The CPLX1 antibody targets Complexin-1 (CPLX1), a small, soluble synaptic protein critical for regulating neurotransmitter release in neurons. As a key component of the synaptic vesicle fusion machinery, CPLX1 modulates the SNARE complex by acting as both a facilitator and inhibitor of synaptic vesicle exocytosis, depending on cellular context. It plays a dual role: stabilizing primed vesicles to enhance synchronization of release while also clamping spontaneous fusion events, ensuring precise control over synaptic transmission. CPLX1 is predominantly expressed in the brain, particularly in regions rich in excitatory and inhibitory synapses, making it essential for studying synaptic plasticity, neural circuit function, and neurodevelopmental or psychiatric disorders. Antibodies against CPLX1 are widely used in neuroscience research for applications like Western blotting, immunohistochemistry, and immunofluorescence to visualize protein distribution, quantify expression levels, or investigate alterations in synaptic dynamics under pathological conditions (e.g., epilepsy, schizophrenia). Their specificity and reliability make them vital tools for exploring synaptic dysfunction mechanisms and validating experimental models of neurological diseases. Commercial CPLX1 antibodies are typically validated for reactivity across species, including human, mouse, and rat.